» Articles » PMID: 23001546

Reduced Plasma Ghrelin Levels on Day 1 After Esophagectomy: a New Predictor of Prolonged Systemic Inflammatory Response Syndrome

Overview
Journal Surg Today
Specialty General Surgery
Date 2012 Sep 25
PMID 23001546
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Ghrelin, a stomach-derived hormone, stimulates growth hormone secretion and appetite, and inhibits excessive inflammatory response. Plasma ghrelin might affect the inflammatory response to stressful surgical interventions. The aim of this study was to investigate the relationship between serial changes in plasma ghrelin concentrations and the postoperative clinical course after esophagectomy.

Methods: The prospective cohort study subjects were 20 patients with esophageal cancer, who underwent esophagectomy with gastric tube reconstruction. Blood samples were taken six times perioperatively during the course of esophagectomy.

Results: The plasma ghrelin level decreased to 33 % (range 15-90 %) on postoperative day (POD) 1, relative to the preoperative level, then recovered to about 50 % by POD 3-10. The duration of systemic inflammatory response syndrome (SIRS) was significantly longer in patients with a marked ghrelin reduction to <33 % on POD 1, than in those with less marked reduction of ≥ 33 % (6.1 ± 1.3 vs. 2.1 ± 0.6 days, P = 0.019). On POD 1, the only inflammatory marker that correlated with the duration of SIRS was the % ghrelin, whereas C-reactive protein, leukocyte count, and IL-6 did not.

Conclusion: An early postoperative drop in plasma ghrelin correlated with prolonged SIRS after esophagectomy. Thus, the supplementation of low plasma ghrelin may help minimize excess inflammatory response in these patients.

Citing Articles

Effect of ghrelin administration on postoperative inflammatory response and bodyweight loss in patients with oesophageal cancer undergoing oesophagectomy: a systematic review and meta-analysis.

Forshaw E, Hajibandeh S, Hajibandeh S Langenbecks Arch Surg. 2023; 408(1):232.

PMID: 37314533 PMC: 10267258. DOI: 10.1007/s00423-023-02970-w.


Diverse and Complementary Effects of Ghrelin and Obestatin.

Villarreal D, Pradhan G, Zhou Y, Xue B, Sun Y Biomolecules. 2022; 12(4).

PMID: 35454106 PMC: 9028691. DOI: 10.3390/biom12040517.


Protective and Healing Effects of Ghrelin and Risk of Cancer in the Digestive System.

Ginter G, Ceranowicz P, Warzecha Z Int J Mol Sci. 2021; 22(19).

PMID: 34638910 PMC: 8509076. DOI: 10.3390/ijms221910571.


Cancer Recurrence After Esophagectomy: Impact of Postoperative Infection in Propensity-Matched Cohorts.

Tam V, Luketich J, Winger D, Sarkaria I, Levy R, Christie N Ann Thorac Surg. 2016; 102(5):1638-1646.

PMID: 27353482 PMC: 5436488. DOI: 10.1016/j.athoracsur.2016.04.097.


Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial.

Yanagimoto Y, Takiguchi S, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y Br J Cancer. 2016; 114(12):1318-25.

PMID: 27253174 PMC: 4984476. DOI: 10.1038/bjc.2016.160.


References
1.
Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W . Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001; 104(12):1430-5. DOI: 10.1161/hc3601.095575. View

2.
Sato N, Koeda K, Ikeda K, Kimura Y, Aoki K, Iwaya T . Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg. 2002; 236(2):184-90. PMC: 1422564. DOI: 10.1097/00000658-200208000-00006. View

3.
Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K . Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005; 128(3):1187-93. DOI: 10.1378/chest.128.3.1187. View

4.
Opal S, Fisher Jr C, Dhainaut J, Vincent J, Brase R, Lowry S . Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997; 25(7):1115-24. DOI: 10.1097/00003246-199707000-00010. View

5.
Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W . Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004; 110(24):3674-9. DOI: 10.1161/01.CIR.0000149746.62908.BB. View